FFA
TNGX icon

Farther Finance Advisors’s Tango Therapeutics TNGX Stock Holding History

Farther Finance Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.37K Sell
55
-322
-85% -$8.38K ﹤0.01% 5499
2026
Q2 		$11.8K Buy
377
+5
+1% +$124 ﹤0.01% 4317
2026
Q1 		$7.89K Buy
372
+17
+5% +$237 ﹤0.01% 4258
2025
Q4 		$3.15K Buy
355
+330
+1,320% +$2.84K ﹤0.01% 4516
2025
Q3 		$210 Buy
+25
New +$169 ﹤0.01% 4710
2025
Q2 		– Sell
-1,572
Closed -$2.01K – 4655
2025
Q1 		$2.01K Buy
+1,572
New +$3.86K ﹤0.01% 3392
2024
Q4 		– Sell
-5
Closed -$39 – 4144
2024
Q3 		$39 Hold
5
– – ﹤0.01% 3884
2024
Q2 		$45 Hold
5
– – ﹤0.01% 3704
2024
Q1 		$38 Hold
5
– – ﹤0.01% 3487
2023
Q4 		$50 Buy
+5
New +$43 ﹤0.01% 3381

Other funds holding TNGX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's TNGX Position: Q3 2026 in Review

Farther Finance Advisors reduced its Tango Therapeutics (TNGX) stake by 85% in Q3 2026, selling an estimated $8.38K and leaving 55 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #5499.

Farther Finance Advisors first reported a position in TNGX in Q4 2023 and has held it in 10 quarters since. The position peaked at $11.8K in Q2 2026. 3 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

  • Farther Finance Advisors held 55 shares of Tango Therapeutics worth $1.37K as of Q3 2026.
  • Farther Finance Advisors sold 322 Tango Therapeutics shares in Q3 2026, an estimated $8.38K.
  • Tango Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5499 holding.
  • Farther Finance Advisors first reported a position in Tango Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Farther Finance Advisors's Tango Therapeutics position peaked at $11.8K in Q2 2026.
  • 3 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.